# OnCo record plx-61639 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/plx-61639/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "plx-61639" ;
  schema:name "PLX-61639"@en ;
  schema:description "PLX-61639 is an experimental oral monovalent direct protein degrader from Plexium, in phase 1 trials for SMARCA4-mutant locally advanced or metastatic solid tumours, non-small cell lung cancer and oesophageal and gastric cancers."@en ;
  schema:url <https://onco.cc/drugs/plx-61639/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://plexium.com/pipeline/>, <https://plexium.com/clinical-trials/>, <https://clinicaltrials.gov/study/NCT07284186>, <https://clinicaltrials.gov/search?intr=PLX-61639> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral monovalent direct protein degrader" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/gastric/> ;
  onco:targets <https://onco.cc/targets/smarca2/> ;
  onco:companies <https://onco.cc/companies/plexium/> ;
  onco:trials <https://onco.cc/trials/nct07284186/> .